Eli Lilly and Co., of Indianapolis, reported results from an analyses of five datasets evaluating the relationship between cognitive and functional impairment in patients with mild Alzheimer's disease in the natural course of the disease. Analysis findings demonstrated that cognitive deficits predict subsequent functional deficits and suggested that cognitive decline experienced by patients is followed by an observable related decline in function, consistent with previously proposed hypotheses. Data were presented at the Alzheimer's Association International Conference in Copenhagen. The objective of the study was to better understand the relationship between cognitive and functional decline in mild Alzheimer's disease by using pooled data from placebo patients from the solanezumab EXPEDITION and EXPEDITION2 trials and the semagacestat IDENTITY and IDENTITY2 trials, as well as data from the Alzheimer's Disease Neuroimaging Initiative study, which is an observational study.
Novartis AG, of Basel, Switzerland, is partnering with researchers from the Banner Alzheimer's Institute in a medical trial to determine whether two investigational anti-amyloid drugs – an active immunotherapy and an oral medication – can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages. The five-year APOE4 trial will involve more than 1,300 cognitively healthy older adults, ages 60 to 75, at high risk of developing symptoms of Alzheimer's because they inherited two copies of the apolipoprotein E (APOE4) gene. The trial, subject to regulatory approval, will begin in 2015.